News

Havas Lynx has announced the appointment of Talin Apkarian as Havas Lynx Hudson managing director.
Merck & Co – known as MSD outside of the US and Canada – has unveiled a new cost-cutting plan aimed at saving $3bn every year by the end of 2027.
Walawalkar most recently served as chief strategy officer, international brands at MullenLowe Global, part of IPG ...
Moderna’s LP.8.1-adapted COVID-19 vaccine has been recommended by the European Medicines Agency (EMA)’s human medicines ...
Our strategist Stephanie Goley, MSc, PhD takes a fascinating look at how advertising is breaking down stigmas around areas of ...
AstraZeneca’s Imfinzi (durvalumab) has been granted priority review by the US Food and Drug Administration (FDA) to treat ...
HealthEconomics.com interviews David W. Miller, CEO of Genesis Research Group, to discuss the unique challenges faced by ...
Here, Evelyne Priestman (Senior Consultant – HEOR) and Mary Baker (Senior Medical Writer) at Petauri Evidence explore the ...
In a significant step towards tackling one of the UK’s most underdiagnosed conditions, North East and North Cumbria ...
Roche has shared new data from its Alzheimer’s disease (AD) development portfolio at this year’s Alzheimer’s Association ...
With the decline in UK public health campaign funding, we have explored the unique opportunity presented to the ...
Novartis and Matchpoint Therapeutics have entered into a partnership worth $1bn to develop oral inhibitors for inflammatory ...